The thesis
PanicFade v4 is a contrarian mean-reversion strategy built on a simple behavioral premise: negative headline shocks are overreacted to, and prices revert toward fundamentals. It buys large caps hit by sentiment below -0.4 while they are already oversold — RSI14 under 35 and trading below their SMA20 — and sizes into the panic. Exits come on reversion (RSI14 back above 50 or a reclaim of SMA20), with a hard stop on fresh lows under continued negativity, treated as a genuine fundamental break rather than noise.
The design leans on recent sentiment-feedback literature (arXiv:2509.11970 and corroborating work on stock-level investor sentiment). It restricts itself to a 24-name blue-chip universe — AAPL, MSFT, JPM, XOM, and the like — which sensibly keeps the panic-fade away from illiquid small caps where an overreaction can just be a correct repricing.
Validation: genuinely encouraging
This is where PanicFade v4 earns its keep. The walk-forward test ran four sequential folds spanning September 2021 to August 2026, and all four came back positive — 1.6%, 3.88%, 10.14%, and 21.7%. Crucially, performance improved across folds while max drawdown fell to just 2.6% in the most recent window. Out-of-sample return of 21.7% at an OOS Sharpe of 2.44 is strong.
The deflated statistics are the real signal. A Probabilistic Sharpe Ratio of 0.985 says the observed Sharpe is very unlikely to be luck, and a Deflated Sharpe Ratio of 0.56 — after accounting for 27 trials — remains positive. That the DSR survives the multiple-testing haircut is more reassuring than the headline 37.93% total return, which annualizes to a modest 6.79% CAGR.
The risks
Two things temper the enthusiasm. First, the full-sample Sharpe is only 0.96 — under 1.0, and well below the flattering OOS figure. The strategy's strength is concentrated in the final fold; earlier folds were merely fine. Turnover is also extreme at 5,807%, so execution slippage beyond the modeled $530 in fees could bite harder in the wild.
Second, and more immediately: the live book is doing nothing. Every scheduled run from August 6 through August 13 executed zero trades and rejected zero — cash and total equity have sat pegged at $10,000 the entire time. That is not necessarily a fault; a panic-fade strategy should stay flat when no name in its universe is simultaneously oversold and sentiment-battered. Markets have simply not handed it a setup. But it means the live track record is currently empty, and all the confidence above rests on backtest and walk-forward data, not realized paper trades.
Verdict
PanicFade v4 is one of the better-validated strategies in the stable: four-for-four positive folds, a PSR near certainty, and a positive deflated Sharpe. The honest caveat is that it is a patient strategy by construction — it waits for genuine panic — and right now it is waiting. Judge it on whether it deploys cleanly the next time the tape sells off, not on this quiet week.